National Heart, Lung, and Blood Institute; Notice of Meetings, 58263-58264 [2018-25192]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 223 / Monday, November 19, 2018 / Notices
khammond on DSK30JT082PROD with NOTICES
Intellectual Property
E–133–2016: FLT3-Specific Chimeric
Antigen Receptors and Methods Using
Same
1. US Provisional Patent Application
62/342,394, filed May 27, 2016 (E–133–
2016–0–US–01);
2. International Patent Application
PCT/US2017/034,691, filed May 26,
2017 (E–133–2016–0–PCT–02)
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
fields of use may be limited to the
following:
‘‘The development of a mono- or
multi-specific FMS-like tyrosine kinase
3 (FLT3; also known as CD135) chimeric
antigen receptor (CAR)-based
immunotherapy using autologous or
allogenic human lymphocytes (T cells
or NK cells) transduced with lentiviral
vectors, wherein the viral transduction
leads to the expression of a CAR that
targets FLT3 (comprised of the FLT3binding domain referenced as NC7 in
the invention as well as an intracellular
signaling domain), for the prophylaxis
or treatment of FLT3-expressing
cancers.’’
This technology discloses a CAR
vector that targets FLT3 comprised of an
anti-FLT3 antibody known as NC7, and
an intracellular signaling domain. FLT3
(CD135) is a cytokine receptor expressed
on hematopoietic progenitor cells, and
is one of the most frequently mutated
genes in acute myeloid leukemia (AML)
and infant acute lymphoblastic
leukemia (ALL). FLT3 mutation leads to
increased cell surface expression and
therefore on leukemic cells, which
makes it an attractive candidate for
cellular therapies such as CAR–T.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
VerDate Sep<11>2014
17:20 Nov 16, 2018
Jkt 247001
58263
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: November 8, 2018.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2018–25197 Filed 11–16–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR18–822:
Approaches for Understanding Disease
Mechanisms and Improving Outcomes in TB
Meningitis (TBM).
Date: December 12, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Guangyong Ji, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3211,
MSC 7808, Bethesda, MD 20892, 301–435–
1146, jig@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25196 Filed 11–16–18; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meetings
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Catalyzing Innovation in Trial Design.
Date: December 6, 2018.
Time: 10:00 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892, 301–827–7913, creazzotl@
mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Catalyzing Innovation in Trial Design
Resource Access.
Date: December 6, 2018.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892, 301–827–7913, creazzotl@
mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Integrative Computational Biology for
Analysis of NHLBI TOPMed Data.
Date: December 7, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Susan Wohler Sunnarborg,
Ph.D., Scientific Review Officer, Office of
E:\FR\FM\19NON1.SGM
19NON1
58264
Federal Register / Vol. 83, No. 223 / Monday, November 19, 2018 / Notices
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6701 Rockledge Drive, Room 7182,
Bethesda, MD 20892, susan.sunnarborg@
nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
R25: Short-Term Research Education to
Increase Diversity.
Date: December 7, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Lindsay M. Garvin, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Suite 7189, Bethesda, MD
20892, 301–827–7911, lindsay.garvin@
nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Institutional Training Grants.
Date: December 12, 2018.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7192, Bethesda, MD
20892, 301–827–7696, Pintuccig@
nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 14, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25192 Filed 11–16–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSK30JT082PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
VerDate Sep<11>2014
17:20 Nov 16, 2018
Jkt 247001
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Infectious
Diseases and Microbiology Fellowships.
Date: November 20, 2018.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Tamara Lyn McNealy,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3188,
Bethesda, MD 20892, 301–827–2372,
tamara.mcnealy@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25195 Filed 11–16–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Date: December 4, 2018.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Deanna Lynn Adkins,
Ph.D., Scientific Review Officer, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20892–
9529, (301) 496–9223, Deanna.adkins@
nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Clinical Trial Readiness for
Rare Neurological and Neuromuscular
Diseases.
Date: December 4, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Ana Olariu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–9223, ana.olariu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: November 13, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25107 Filed 11–16–18; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Summer Research
Education Experience Programs.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
joint meeting of the NCI Board of
Scientific Advisors (BSA) and National
Cancer Advisory Board (NCAB).
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
E:\FR\FM\19NON1.SGM
19NON1
]]>Agencies
[Federal Register Volume 83, Number 223 (Monday, November 19, 2018)]
[Notices]
[Pages 58263-58264]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25192]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Catalyzing Innovation in Trial Design.
Date: December 6, 2018.
Time: 10:00 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7180, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6701 Rockledge
Drive, Room 7180, Bethesda, MD 20892, 301-827-7913,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Catalyzing Innovation in Trial Design
Resource Access.
Date: December 6, 2018.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7180, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6701 Rockledge
Drive, Room 7180, Bethesda, MD 20892, 301-827-7913,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Integrative Computational Biology for
Analysis of NHLBI TOPMed Data.
Date: December 7, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW, Washington, DC 20015.
Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific
Review Officer, Office of
[[Page 58264]]
Scientific Review/DERA, National Heart, Lung, and Blood Institute,
National Institutes of Health, 6701 Rockledge Drive, Room 7182,
Bethesda, MD 20892, [email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; R25: Short-Term Research Education to
Increase Diversity.
Date: December 7, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Lindsay M. Garvin, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6701 Rockledge
Drive, Suite 7189, Bethesda, MD 20892, 301-827-7911,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; NHLBI Institutional Training Grants.
Date: December 12, 2018.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Giuseppe Pintucci, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6701 Rockledge
Drive, Room 7192, Bethesda, MD 20892, 301-827-7696,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: November 14, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-25192 Filed 11-16-18; 8:45 am]
BILLING CODE 4140-01-P
